By Gwendolyn Wu | Published June 1, 2026
In a decisive move to revitalize its corporate trajectory, Rallybio Corporation has announced a definitive merger agreement with the privately held oncology specialist Avenzo Therapeutics. This transaction marks a critical turning point for the New Haven-based rare disease company, which has spent the last two years navigating a turbulent landscape of clinical setbacks and workforce reductions.
The deal, unveiled on Monday, represents the second attempt by Rallybio to secure its future through a reverse merger within a span of just three months. Following the collapse of a previous agreement with Candid Therapeutics—which was abruptly preempted by a $2.2 billion acquisition by Belgian pharmaceutical giant UCB—Rallybio is now pinning its hopes on Avenzo’s high-potential pipeline of small molecules and antibody-drug conjugates (ADCs).
The Mechanics of the Merger
Under the terms of the agreement, the combined entity will operate under the name Avenzo Therapeutics. The transition is designed to provide Avenzo with the public market access necessary to scale its clinical operations, while simultaneously providing Rallybio shareholders with a stake in a well-capitalized, oncology-focused enterprise.
The merger is bolstered by a massive $215 million concurrent private placement, ensuring that the newly formed company remains well-funded through at least 2028. Upon the deal’s expected closure by the end of 2026, the company will trade on the Nasdaq stock exchange under the ticker symbol "AVZO."
A Chronology of Corporate Restructuring
To understand the significance of this merger, one must look at the recent history of Rallybio, a company that debuted on the public markets in 2021 with high expectations.
- 2021-2023: The Rare Disease Struggle: Rallybio focused on developing therapies for severe, rare maternal and fetal diseases. However, the company faced significant headwinds, most notably the discontinuation of its lead program for FNAIT (fetal and neonatal alloimmune thrombocytopenia) following disappointing clinical data. These failures necessitated a series of corporate restructurings and layoffs as the company sought to preserve its cash runway.
- March 2026: The First Attempt: Recognizing the need for a fundamental shift in business model, Rallybio announced a merger with Candid Therapeutics. The market reacted favorably, with Rallybio’s stock price seeing an immediate surge. The plan was to pivot toward T-cell engagers, a promising class of immunotherapy.
- May 2026: The UCB Intervention: The momentum was short-lived. In a move that underscored the high demand for bispecific T-cell engager technology, UCB swooped in to acquire Candid Therapeutics in a multi-billion dollar transaction, effectively nullifying the merger agreement with Rallybio.
- June 2026: The Avenzo Pivot: Undeterred, the Rallybio leadership team pivoted immediately to Avenzo Therapeutics, a firm that shares the "well-funded biotech" profile that Rallybio had sought in its previous partner.
Supporting Data: The Science Behind Avenzo
Avenzo Therapeutics represents a new breed of biotech firm that focuses on licensing and optimizing therapeutic assets originally developed by Chinese pharmaceutical innovators. Before the merger, Avenzo had successfully banked approximately $450 million in venture capital funding, a testament to the perceived value of its four core experimental assets.
The company’s portfolio is built on a foundation of "next-generation" drug design, specifically targeting well-validated pathways with the goal of improving clinical outcomes over existing standards of care:
- Next-Generation CDK Inhibitors: Avenzo is advancing two inhibitors targeting CDK2, a protein heavily implicated in cell cycle progression in breast cancer. By aiming for higher selectivity than current market leaders like Ibrance (palbociclib) and Verzenio (abemaciclib), Avenzo hopes to reduce off-target toxicity and improve efficacy. Updated early-stage data for the lead candidate, AVZO-021, was presented this week at the American Society of Clinical Oncology (ASCO) annual meeting, reinforcing the company’s scientific credibility.
- Bispecific Antibody-Drug Conjugates (ADCs): The company’s pipeline also features two bispecific ADCs. While traditional ADCs are powerful, they often target a single antigen. Avenzo’s dual-targeting approach aims to increase the precision of drug delivery to tumor cells, potentially overcoming resistance mechanisms that often arise in patients treated with traditional therapies.
All four of these experimental assets are currently in Phase 1 clinical studies, providing a wide surface area for potential data-driven catalysts over the next several years.
Official Responses and Leadership Transitions
The new iteration of Avenzo Therapeutics will be helmed by its current CEO, Athena Countouriotis, with co-founder and Chief Medical Officer Dr. Mohammad Hirmand overseeing the clinical execution.
In a formal statement following the announcement, Countouriotis framed the merger as a strategic imperative: "This is a turning point for Avenzo. The integration provides us with the necessary resources and the public platform to aggressively advance our pipeline beyond multiple potential data readouts. Our focus remains on bringing these next-generation therapies to patients as efficiently as possible."
The financial backing for this transition is substantial. The $215 million private placement saw participation from an elite group of investors, including Blackstone Multi-Asset Investing, T. Rowe Price Investment Management, OrbiMed, SR One, and Foresite Capital. The participation of these institutional heavyweights suggests a strong vote of confidence in the underlying science and the leadership team’s ability to execute a complex integration.
Implications: The "China-to-Global" Pipeline Model
The merger between Rallybio and Avenzo highlights a broader trend in the biotech sector: the integration of high-quality R&D from the Chinese pharmaceutical ecosystem into the global drug development engine.
Both Candid Therapeutics and Avenzo Therapeutics were built around intellectual property acquired from Chinese firms like VelaVigo, DualityBio, and Allorion Therapeutics. This model allows Western biotech companies to bypass the high-risk, early-stage discovery phase, instead acquiring candidates that have already shown promise in laboratory and early clinical settings. By combining these assets with the clinical development expertise and capital market access inherent in a US-based public company, these firms aim to accelerate the path to market.
However, the strategy is not without risks. As seen with the collapse of the Candid deal, the "well-funded, high-potential" profile makes these companies attractive targets for acquisition by Big Pharma. For Rallybio, this creates a double-edged sword: while the merger provides a new lease on life, the company’s long-term independence is inherently tied to its ability to develop its assets faster than they can be snapped up by industry giants.
For the biotech industry at large, the Avenzo-Rallybio deal serves as a case study in resilience. It demonstrates how companies in the "struggling" category can leverage their public status as a currency to capture value, provided they are willing to completely abandon failing legacy programs in favor of high-growth therapeutic areas. As the industry looks toward the second half of 2026, all eyes will be on the Phase 1 readouts from the new Avenzo pipeline to see if this pivot can truly deliver the transformative results that shareholders and patients demand.
About the Author
